Finsterer Josef, Scorza Fulvio A, Scorza Carla A, Fiorini Ana C
Neurological Department, Messerli Institute, Vienna 1180, Austria.
Department of Neurology, University of Sao Paolo, Sao Paolo 01000-000, Brazil.
World J Virol. 2022 Jan 25;11(1):82-84. doi: 10.5501/wjv.v11.i1.82.
Although several considerations have been raised suggesting a beneficial effect of N-acetyl cysteine (NAC) for the treatment of severe acute respiratory syndrome coronavirus 2 infection, there is currently no clinical evidence that NAC truly prevents coronavirus disease 2019 (COVID-19), reduces the severity of the disease, or improves the outcome. Appropriately designed clinical trials are warranted to prove or disprove a therapeutic effect of NAC for COVID-19 patients.
尽管已经提出了一些考虑因素，表明N-乙酰半胱氨酸（NAC）对治疗严重急性呼吸综合征冠状病毒2感染有有益作用，但目前尚无临床证据表明NAC能真正预防2019冠状病毒病（COVID-19）、降低疾病严重程度或改善预后。有必要进行设计合理的临床试验，以证实或反驳NAC对COVID-19患者的治疗效果。
